Table 2.
Guidelines for the pharmacological management of GDM that is not adequately controlled with medical nutrition therapy and physical activity.
| Society | First Line | Second Line |
|---|---|---|
| ACOG | Insulin | Metformin |
| ADA | Insulin | Metformin or glyburide |
| IDF | Insulin | Metformin |
| WHO | Insulin | Metformin |
| FIGO | Insulin | Metformin |
| PDA/PSGO | Insulin | None |
| DIPSI | Insulin | Metformin |
| SID | Insulin | None * |
| NICE | Metformin | Insulin |
| SMFM | Insulin or metformin | Glyburide |
ACOG: American College of Obstetricians and Gynecologists; ADA: American Diabetes Association; WHO: The World Health Organization; IDF: International Diabetes Federation; FIGO: International Federation of Gynecology and Obstetrics; PDA: Polish Diabetes Association; PSGO: Polish Society of Gynecologists and Obstetricians; DIPSI: Diabetes in Pregnancy study Group India; SID: Italian Diabetes Society; NICE: The British National Institute for Health and Care Excellence; SMFM: Society for Maternal-Fetal Medicine. * Starting from July 2023, SID has opened to the potential administration of extended release metformin in pregnancy, within specific and individualized situations [133].